Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
Her installations include a diverse array of objects: family photographs, an Axminster carpet, a vintage Ford Escort adorned with a giant crocheted doily, the iconic Scottish drink Irn-Bru, and kinetic hand bells. These elements are brought together to reflect the London-based artist’s upbringing in Scotland.
“I’ve received so many messages today from people in the local Sikh community and others I grew up with. Something this visible holds deep meaning for many different groups, and I’m proud to represent them all,” said Kaur.
Kaur initially studied jewellery making before transitioning to applied art, which sparked her interest in creating objects that tell stories through their combinations.
Her exhibition, along with those of the three other shortlisted artists, is on display at the Tate Britain Museum by the River Thames until mid-February 2025.
Linsey Young, co-curator of the exhibition, described Kaur’s installations as addressing “anti-colonialist discussions, anti-imperialist struggles, and a reflection of her lived experience, family, and upbringing.”
Young highlighted one central piece: a vintage Ford Escort covered in a crocheted cotton doily. “The car symbolises one of her father’s aspirations as a migrant who moved from India to Glasgow. Owning such a car was an ambition. The doily, a domestic object made on a large scale, connects to the history of migration and labour—particularly of Indian workers in the North of England after the war, many of whom worked in cotton mills,” she explained.
Other pieces in Kaur’s display include a harmonium placed on a lush carpet, inviting visitors to sit and engage with kinetic worship bells. A central feature is Yearnings 2023, an improvised vocal soundscape of the artist’s voice layered with snippets of pop songs. This music plays from the speakers of Sociomobile 2023—the vintage Ford Escort—filling the space with echoes of Kaur’s musical memories.
The Turner Prize jury commended her for her “evocative combination of sound and sculpture to address family memory and community struggle.”
An accompanying film in the exhibition explores the Sikh concept of Miri Piri, which emphasises a balance between the political and spiritual. Through her art, Kaur seeks to explore pathways for humanity to coexist harmoniously.
Established in 1984 and named after British painter J.M.W. Turner, the prestigious art prize is awarded to an artist born or based in the UK for an outstanding exhibition or presentation of their work in the past 12 months.
Previous victors include now-household names such as duo Gilbert & George, British Indian Anish Kapoor, Rachel Whiteread, Antony Gormley, Chris Ofili, Steve McQueen and Damien Hirst.
British artist Jesse Darling won last year's prize for his sculptures and installations that invoke societal breakdown.
The annual award seeks to encourage debate around new advances in contemporary art and is given to a visual artist based or born in Britain.
But that debate has often spilled over into controversy. Ofili, for example, won in 1998 for incorporating elephant dung into his paintings.
Hirst in 1995 exhibited pieces including a rotting cow's head, while Tracey Emin's 1999 entry "My Bed" -- an unmade double bed with stained sheets surrounded by soiled underwear, condoms, slippers and empty drink bottles -- attracted huge attention.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.